0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Evolving Fluoroquinolone Resistance Among Coagulase-Negative Staphylococcus Isolates Causing Endophthalmitis FREE

Andrew M. Schimel, MD; Darlene Miller, DHSc; Harry W. Flynn, MD
[+] Author Affiliations

Author Affiliations: Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. Dr Schimel is now also with the Center for Excellence in Eye Care, Miami.


Arch Ophthalmol. 2012;130(12):1617-1618. doi:10.1001/archophthalmol.2012.2348.
Text Size: A A A
Published online

Endophthalmitis is a serious, sight-threatening condition resulting in substantial morbidity. With the widespread use of fluoroquinolone antibiotic eyedrops as a prophylactic agent, there is concern regarding increased frequency of fluoroquinolone resistance. We report the evolution of fluoroquinolone resistance among coagulase-negative Staphylococcus endophthalmitis isolates at the Bascom Palmer Eye Institute.

The study was approved by the Institutional Review Board of the University of Miami School of Medicine Medical Sciences Subcommittee for the Protection of Human Subjects. This was a retrospective, noncomparative, consecutive case series. We reviewed the microbiological and medical records of all patients with culture-proven endophthalmitis (positive cultures from the vitreous cavity) caused by coagulase-negative Staphylococcus at the Bascom Palmer Eye Institute between January 1, 1990, and July 1, 2011. Susceptibility testing of the intraocular isolates was performed using an automated system—the VITEK automatic microbial system (Biomérieux, Inc) or the E test (AB Biodisk NA, Inc and Remel Products). Frozen isolates were reconstituted as needed to evaluate sensitivities of earlier cases to newer-generation fluoroquinolones.

During the 21.5 years of the current study, 168 patients were identified as having culture-proven endophthalmitis caused by coagulase-negative Staphylococcus. The increasing resistance rates are shown in the Figure for 1990 to 1994 (n = 29), 1995 to 1999 (n = 23), 2000 to 2004 (n = 26), and 2005 to 2011 (n = 89). The respective resistances (in percentages) of the first 3 periods are the following: ciprofloxacin resistance, 10.3%, 17.4%, and 38.4%; levofloxacin resistance, 0%, 17.0%, and 38.4%; moxifloxacin resistance, 0%, 21.8%, and 26.9%; and gatifloxacin resistance, 0%, 21.8%, and 30.7%. The mean resistance rates for January 1, 2005, through July 1, 2011 (n = 89), were 60.5% for ciprofloxacin, 58.6% for levofloxacin, 57.8% for moxifloxacin, and 60.5% for gatifloxacin (Figure).

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Percentage of fluoroquinolone-resistant coagulase-negative Staphylococcus isolates causing endophthalmitis at the Bascom Palmer Eye Institute during the past 21.5 years. Data are divided by each fluoroquinolone antibiotic.

Despite the dual mechanisms of fluoroquinolones to avoid resistance to coagulase-negative Staphylococcus, the frequency of resistance to these organisms is increasing. Recent evidence shows that repeated exposure of ocular and nasopharyngeal flora to ophthalmic antibiotics, including fluoroquinolones, creates resistant strains.1,2 It has further been shown that resistant strains of coagulase-negative Staphylococcus may be associated with greater ocular inflammation, greater virulence, and increased ocular infection rates compared with susceptible strains.3,4

Fourth-generation fluoroquinolones are significantly more expensive than generic traditional antibiotic eyedrops such as gentamicin sulfate and polymyxin B sulfate/trimethoprim, which have been shown to cover endophthalmitis isolates at least as well.5 Additional recent reports demonstrate that the fourth-generation fluoroquinolones achieve subtherapeutic levels in the aqueous humor and vitreous against the most frequently identified staphylococcal endophthalmitis isolates.6 Given the frequent and increasing resistance, subtherapeutic penetration, and higher cost compared with other antibiotic eyedrops, the widespread perioperative and periprocedural use of fourth-generation fluoroquinolone antibiotic eyedrops should be reevaluated.

Correspondence: Dr Flynn, Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St, Miami, FL 33136 (hflynn@med.miami.edu).

Conflict of Interest Disclosures: None reported.

Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance: a randomized, controlled study of patients undergoing intravitreal injections.  Ophthalmology. 2011;118(7):1358-1363
PubMed
Kim SJ, Toma HS, Midha NK, Cherney EF, Recchia FM, Doherty TJ. Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections.  Ophthalmology. 2010;117(12):2372-2378
PubMed   |  Link to Article
Miño De Kaspar H, Hoepfner AS, Engelbert M,  et al.  Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model.  Ophthalmology. 2001;108(3):470-478
PubMed   |  Link to Article
Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.  Arch Ophthalmol. 2006;124(4):479-483
PubMed   |  Link to Article
Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases.  Am J Ophthalmol. 2004;137(1):38-42
PubMed   |  Link to Article
Donnenfeld ED, Comstock TL, Proksch JW. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.  J Cataract Refract Surg. 2011;37(6):1082-1089
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Percentage of fluoroquinolone-resistant coagulase-negative Staphylococcus isolates causing endophthalmitis at the Bascom Palmer Eye Institute during the past 21.5 years. Data are divided by each fluoroquinolone antibiotic.

Tables

References

Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance: a randomized, controlled study of patients undergoing intravitreal injections.  Ophthalmology. 2011;118(7):1358-1363
PubMed
Kim SJ, Toma HS, Midha NK, Cherney EF, Recchia FM, Doherty TJ. Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections.  Ophthalmology. 2010;117(12):2372-2378
PubMed   |  Link to Article
Miño De Kaspar H, Hoepfner AS, Engelbert M,  et al.  Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model.  Ophthalmology. 2001;108(3):470-478
PubMed   |  Link to Article
Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.  Arch Ophthalmol. 2006;124(4):479-483
PubMed   |  Link to Article
Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases.  Am J Ophthalmol. 2004;137(1):38-42
PubMed   |  Link to Article
Donnenfeld ED, Comstock TL, Proksch JW. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.  J Cataract Refract Surg. 2011;37(6):1082-1089
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles